Bellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of NASDAQ:BLPH opened at $0.04 on Friday. The firm has a fifty day moving average price of $0.04 and a 200 day moving average price of $0.05. Bellerophon Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $0.10. The firm has a market cap of $452,510.00, a price-to-earnings ratio of -0.04 and a beta of 0.71.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.